Cochrane Review: Dipyridamole for Preventing Major Vascular Events in Patients With Vascular Disease

Background— Patients enrolled in clinical trials after nondisabling cerebral ischemia have an annual risk of vascular events (death from all vascular causes, nonfatal stroke, or nonfatal myocardial infarction) of 4% to 11%. Aspirin reduces the incidence by 13%. Many trials in patients presenting with vascular disease investigated the efficacy of (addition of) dipyridamole in secondary prevention. We systematically compared the efficacy and safety of dipyridamole versus control in the presence and absence of other antiplatelet drugs in clinical trials on the secondary prevention of vascular events in patients with vascular disease. Summary of Review— Randomized trials with concealed treatment allocation in patients with a nonembolic arterial vascular disease were selected. Therapy consisted of dipyridamole in the presence or absence of other antiplatelet drugs compared with no drug or an antiplatelet drug(s) other than dipyridamole. Twenty-six trials were included, with a total of 19 842 patients. Dipyridamole was not more efficacious in the prevention of vascular death (relative risk [RR], 1.02; 95% CI, 0.90 to 1.17). It appeared more efficacious in the prevention of vascular events (RR, 0.90; 95% CI, 0.83 to 0.98), but this result only reached statistical significance because of 1 large trial in patients presenting with cerebral ischemia. Combination treatment of dipyridamole and aspirin compared with aspirin had an RR of 1.03 (95% CI, 0.87 to 1.22) for vascular death and an RR of 0.90 (95% CI, 0.80 to 1.00) for vascular events. Conclusions— For patients who presented with arterial vascular disease, there was no evidence that dipyridamole, in the presence or absence of another antiplatelet drug (chiefly aspirin), reduced the risk of vascular death, although it may reduce the risk of further vascular events. However, this benefit was found only in a single large trial and only in patients presenting after cerebral ischemia. There was no evidence that dipyridamole alone was more efficacious than aspirin. Further trials comparing the effects of the combination of dipyridamole plus aspirin with aspirin alone are justified.

[1]  Hans-Christoph Diener,et al.  European Stroke Prevention Study 2. Efficacy and safety data. , 1997, Journal of the neurological sciences.

[2]  L. Wilkins.  European Stroke Prevention Study. ESPS Group. , 1990, Stroke.

[3]  N. Delanty.  Secondary prevention after cerebral ischaemia of presumed arterial origin: is aspirin still the touchstone? , 1999, Journal of neurology, neurosurgery, and psychiatry.

[4]  E. D. De Schryver.  ESPRIT: Protocol Change , 2001, Cerebrovascular Diseases.

[5]  E. de Schryver.  Design of ESPRIT: An International Randomized Trial for Secondary Prevention after Non-Disabling Cerebral Ischaemia of Arterial Origin , 2000, Cerebrovascular Diseases.

[6]  E.L.L.M. De Schryver.  ESPRIT: protocol change. , 2001 .

[7]  C Warlow,et al.  The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. , 1991, Journal of neurology, neurosurgery, and psychiatry.

[8]  M. Catalano,et al.  Treatment of claudication with dipyridamole and aspirin. , 1986, International journal of clinical pharmacology research.

[9]  E. Hutchinson,et al.  Controlled Trial of Dipyridamole in Cerebral Vascular Disease , 1969, British medical journal.

[10]  A. Algra,et al.  Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin , 1999, Journal of neurology, neurosurgery, and psychiatry.

[11]  R. Schlant,et al.  Dipyridamole in the Treatment of Angina Pectoris: A Double-Blind Evaluation , 1967 .

[12]  J. Oates,et al.  Drug therapy. Dipyrimadole , 1987 .

[13]  P. Touboul,et al.  "AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. , 1983, Stroke.

[14]  R. Sacco,et al.  Antithrombotic and thrombolytic therapy for ischemic stroke. , 1998, Chest.

[15]  A. Algra,et al.  SECONDARY PREVENTION AFTER CEREBRAL ISCHAEMIA OF PRESUMED ARTERIAL ORIGIN : IS ASPIRIN STILL THE TOUCHSTONE? AUTHORS' REPLY , 1999 .

[16]  J. Tijssen,et al.  Low-dose and high-dose acetylsalicylic acid, with and without dipyridamole: a review of clinical trial results. , 1998, Neurology.

[17]  Effect of Aspirin Alone and Aspirin Plus Dipyridamole in Early Diabetic Retinopathy: A Multicenter Randomized Controlled Clinical Trial , 1989, Diabetes.

[18]  J. Himmelfarb,et al.  Anti-platelet therapy in graft thrombosis: results of a prospective, randomized, double-blind study. , 1994, Kidney international.

[19]  A. Algra,et al.  A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. , 1991, The New England journal of medicine.

[20]  A. Connor,et al.  The way I see it: House officers need formal career development , 2002 .

[21]  Misra Np,et al.  Comparative trial of sulphinpyrazone and aspirin+dipyridamole in acute myocardial infarction , 1983 .

[22]  A. Mattioli,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[23]  A. Algra,et al.  Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[24]  A. Lowenthal.  The European Stroke Prevention Study , 1988, Acta neurologica Belgica.

[25]  Catherine Sudlow,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[26]  M. Wirecki.  Treatment of angina pectoris with dipyridamole: a long-term double blind study. , 1967, Journal of Chronic Diseases.

[27]  E. Schryver.  Design of ESPRIT: An International Randomized Trial for Secondary Prevention after Non-Disabling Cerebral Ischaemia of Arterial Origin , 2000 .

[28]  Walker,et al.  Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients , 1994 .

[29]  M. C. Igloe.  TREATMENT OF ANGINA PECTORIS WITH DIPYRIDAMOLE: A DOUBLE‐BLIND STUDY , 1970, Journal of the American Geriatrics Society.

[30]  L. Wilkins.  Persantine Aspirin Trial in cerebral ischemia. Part II: Endpoint results. The American-Canadian Co-Operative Study group. , 1985 .

[31]  J. Sy,et al.  Effects of Recombinant Human Growth Hormone on Height and Skeletal Maturation in Growth Hormone-Deficient Children with and without Severe Pretreatment Bone Age Delay , 1999, Hormone Research in Paediatrics.

[32]  S. Caneschi,et al.  [Ischemic cerebrovascular disease: treatment with various anti-platelet aggregation drugs. Clinical follow-up of 80 patients (22-34 months)]. , 1985, Minerva medica.

[33]  A. Einstein,et al.  Persantine Aspirin Trial in cerebral ischemia. Part II: Endpoint results. The American-Canadian Co-Operative Study group. , 1985, Stroke.

[34]  H. Koennecke.  Secondary Prevention of Stroke , 2004, CNS drugs.

[35]  G. Deichsel,et al.  DRUG-INDUCED INHIBITION OF PLATELET FUNCTION DELAYS PROGRESSION OF PERIPHERAL OCCLUSIVE ARTERIAL DISEASE A Prospective Double-Blind Arteriographically Controlled Trial , 1985, The Lancet.